KNOW Bio

KNOW Bio is a privately held life science incubator founded in 2015, built upon two core technology platforms: nitric oxide delivery and precision light therapy. The company creates and funds subsidiary ventures (e.g., EmitBio, Vast Therapeutics, Revian) to develop products for diverse indications, from infectious diseases to dermatology and diabetes care. Its strategy involves advancing subsidiaries to proof-of-concept before seeking exits via sale, IPO, or financing to fund the broader portfolio and generate investor returns.

Proprietary intellectual property portfolio in two areas: 1) Nitric Oxide chemistry, focusing on macromolecular scaffolds for controlled storage and release of NO for therapeutic delivery and device coatings. 2) Precision light therapy using specific wavelengths of LED light to elicit therapeutic biological responses for healing and defense.

Competition is fragmented by subsidiary. Revian competes with other light-based devices (e.g., Capillus), pharmaceuticals (minoxidil, finasteride), and procedures. Vast Therapeutics faces numerous biotechs and pharma companies developing novel antibiotics. Diabetic Health competes with major medical device companies (Dexcom, Abbott, Medtronic) investing in their own CGM sensor biocompatibility. EmitBio would enter a crowded infectious disease space if its programs advance.